EUVIMEDEUVIMED entdecken
Crossref

Effectiveness and Safety of Continuous Intravenous Infusion of Vancomycin in Non-Critically Ill Patients

Siriluk Jaisue

Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci) · 01.01.2024

DOI: 10.14456/ijps.2024.23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci), erschienen am 01.01.2024. Verfasst von Siriluk Jaisue.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vancomycin is an antibiotic commonly used to treat infections caused by Gram-positive bacteria. Recent guideline has suggested to administer the drug as continuous intravenous in critically ill patients. However, there are no specific recommendations for its use in non-critically ill patients.

Objective

To study the use pattern of continuous intravenous vancomycin infusion and its clinical outcomes in non-critically ill patients.

Methods

A retrospective descriptive analysis was conducted on patients receiving continuous intravenous vancomycin at Srinagarind Hospital between January 1, 2010, and October 31, 2023. Effectiveness was measured by early clinical response, end-of-treatment outcomes, target attainment, and 30-day all-cause mortality. Safety outcomes were assessed using the incidence of vancomycin-induced nephrotoxicity. The relationship between vancomycin dose and the plasma drug concentration was assessed using Pearson correlation.

Results

A total of 15 patients were included in the study. The most common infections in patients were bacteremia (33%) and central nervous system infections (20%). Three patients (20%) achieved the target attainment, with a mean dose of 55.5 ± 3.1 mg/kg/day. The improvement was found in 9 patients (60%) in early clinical response and 11 patients (73%) by the end of treatment. No patients experienced 30-day all-cause mortality or nephrotoxicity. A moderately positive correlation between vancomycin dose and the drug concentration was observed, with statistical significance (r2 = 0.523, p-value < 0.05).

Conclusion

Continuous intravenous vancomycin appears to be an effective and safe treatment option for non-critically ill patients, with no evidence of nephrotoxicity in this study.

Schlagwörter

vancomycincontinuous intravenous infusionnon-critically ill patientsantibiotic efficacydrug safetyvancomycin pharmacokinetics

Zitieren

APA

Jaisue, S. (2024). Effectiveness and Safety of Continuous Intravenous Infusion of Vancomycin in Non-Critically Ill Patients. Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci). https://doi.org/10.14456/ijps.2024.23

Vancouver

Jaisue S. Effectiveness and Safety of Continuous Intravenous Infusion of Vancomycin in Non-Critically Ill Patients. Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci). 2024. doi:10.14456/ijps.2024.23

BibTeX
@article{Jaisue2024,
  author = {Jaisue, Siriluk},
  title = {Effectiveness and Safety of Continuous Intravenous Infusion of Vancomycin in Non-Critically Ill Patients},
  journal = {Isan Journal of Pharmaceutical Sciences, IJPS (Isan J Pharm Sci)},
  year = {2024},
  doi = {10.14456/ijps.2024.23}
}
Kostenlos starten →